Trends in the Treatment of Hepatocellular Carcinoma

Author(s): Janine M. Davies, Bert H. O'Neil

Journal Name: Current Drug Therapy

Volume 5 , Issue 2 , 2010

Become EABM
Become Reviewer
Call for Editor


HepatoCellular Carcinoma (HCC) is the fifth most common cancer and the third most common cause of cancer- related deaths. In unresectable disease, chemotherapy has modest response rates without a clear improvement in overall survival. Sorafenib is a multikinase inhibitor that recently demonstrated improved overall survival in two randomized clinical trials. This review paper outlines the basic treatment options for HCC by stage, followed by a discussion of key issues in the treatment and management of patients with HCC: the use of targeted therapies and/or chemotherapy in metastatic disease and in different ethnic groups; the potential use of combination therapies in earlier disease stages; and the role of imaging in the era of targeted therapy and the associated challenges.

Keywords: Hepatocellular carcinoma, sorafenib, multikinase inhibitor, treatment

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2010
Page: [118 - 121]
Pages: 4
DOI: 10.2174/157488510791065111
Price: $65

Article Metrics

PDF: 6